The abstracts for "General Poster Sessions" (including the one for the Phase I/II UK H&N Reolysin Trial) will be publicly released on ASCO.org on Thursday, May 20, at 6:00 PM (EDT).
The recurrent ovarian cancer Reolysin Trial poster, and the Phase II Ras+ NSCLC Reolysin poster, will not be released until the presentation day of these "Trials in Progress Poster Session" presentations (Mon June 7).
I'm not sure what to make of the poster vs oral observation but I have been thinking the same thoughts. Might make a good question for the AGM. I believe the deadline for submission of the presentation to ASCO is rather early January if I remember so the trial status at that point is used so it might be early, updated data will be presented at the conference.
We shall find out in due course. ONCY/ONC is certainly not attracting any positive trading volume. I hope this changes very soon as we are a weekend away from the AGM. Im hopeful that there will be a positive news announcement between now and the AGM next week. I would be thrilled if it was start of enrollment of the Phase III.
Release of ASCO abstracts happens May 20th - Final H&N data from UK The NSCLC poster at ASCO is June 7th - This one is the key one in my mind. Brad has stated that there are potential partners interested more in the NSCLC trial results than the H&N but Im hopeful they both will be PPS movers when publicly released.
3 Major Events in the next month. Should be exciting.
News 
Market Data 
Discover 
AI
